155 related articles for article (PubMed ID: 23706161)
1. OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2.
West NW; Garcia-Vargas A; Chalfant CE; Park MA
BMC Cancer; 2013 May; 13():256. PubMed ID: 23706161
[TBL] [Abstract][Full Text] [Related]
2. OSU-03012 interacts with lapatinib to kill brain cancer cells.
Booth L; Cruickshanks N; Ridder T; Chen CS; Grant S; Dent P
Cancer Biol Ther; 2012 Dec; 13(14):1501-11. PubMed ID: 22990204
[TBL] [Abstract][Full Text] [Related]
3. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
4. OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies.
Booth L; Roberts JL; Tavallai M; Nourbakhsh A; Chuckalovcak J; Carter J; Poklepovic A; Dent P
J Cell Physiol; 2015 Aug; 230(8):1982-98. PubMed ID: 25736380
[TBL] [Abstract][Full Text] [Related]
5. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Singla S; Pippin JA; Drebin JA
Oncol Rep; 2012 Dec; 28(6):2211-6. PubMed ID: 23007710
[TBL] [Abstract][Full Text] [Related]
6. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
[TBL] [Abstract][Full Text] [Related]
7. Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.
Kaczyńska A; Herman-Antosiewicz A
Breast Cancer; 2017 Mar; 24(2):271-280. PubMed ID: 27154770
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
Liu T; Yacoub R; Taliaferro-Smith LD; Sun SY; Graham TR; Dolan R; Lobo C; Tighiouart M; Yang L; Adams A; O'Regan RM
Mol Cancer Ther; 2011 Aug; 10(8):1460-9. PubMed ID: 21690228
[TBL] [Abstract][Full Text] [Related]
9. Nck2 promotes human melanoma cell proliferation, migration and invasion in vitro and primary melanoma-derived tumor growth in vivo.
Labelle-Côté M; Dusseault J; Ismaïl S; Picard-Cloutier A; Siegel PM; Larose L
BMC Cancer; 2011 Oct; 11():443. PubMed ID: 21992144
[TBL] [Abstract][Full Text] [Related]
10. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
11. Nck1, But Not Nck2, Mediates Disturbed Flow-Induced p21-Activated Kinase Activation and Endothelial Permeability.
Alfaidi M; Bhattarai U; Orr AW
J Am Heart Assoc; 2020 Jun; 9(11):e016099. PubMed ID: 32468886
[TBL] [Abstract][Full Text] [Related]
12. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
13. Non-overlapping functions of Nck1 and Nck2 adaptor proteins in T cell activation.
Ngoenkam J; Paensuwan P; Preechanukul K; Khamsri B; Yiemwattana I; Beck-García E; Minguet S; Schamel WW; Pongcharoen S
Cell Commun Signal; 2014 Mar; 12():21. PubMed ID: 24670066
[TBL] [Abstract][Full Text] [Related]
14. Proteomic Analysis of NCK1/2 Adaptors Uncovers Paralog-specific Interactions That Reveal a New Role for NCK2 in Cell Abscission During Cytokinesis.
Jacquet K; Banerjee SL; Chartier FJM; Elowe S; Bisson N
Mol Cell Proteomics; 2018 Oct; 17(10):1979-1990. PubMed ID: 30002203
[TBL] [Abstract][Full Text] [Related]
15. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
Godinho MF; Wulfkuhle JD; Look MP; Sieuwerts AM; Sleijfer S; Foekens JA; Petricoin EF; Dorssers LC; van Agthoven T
Br J Cancer; 2012 Sep; 107(6):947-55. PubMed ID: 22892392
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
Wang YX; Gao JX; Wang XY; Zhang L; Liu CM
Tumour Biol; 2012 Aug; 33(4):957-66. PubMed ID: 22252523
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1.
Kwon YS; Chun SY; Nam KS; Kim S
Oncol Rep; 2015 Aug; 34(2):884-90. PubMed ID: 26063481
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
20. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
